Clinical Trial

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-08-04; most recent amendment 2025-08-05.
Status change: Recruiting → Active, Not Recruiting 2025-06-10
Status change: Not Yet Recruiting → Recruiting 2022-02-08
Trial Details
NCT Number NCT05002127
Lead Sponsor ALX Oncology Inc.
Collaborators: Eli Lilly and Company
Conditions Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Enrollment 127 participants
Start Date 2022-01-15
Primary Completion 2024-05-24 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-07